Advertisement
ACXP Novinky na Forexe
Acurx Announces Positive Microbiology And Microbiome Data For Ibezapolstat From Phase 2b Trial
Biopharmaceutical company Acurx Pharmaceuticals, Inc. (ACXP) announced Wednesday positive comparative microbiology and microbiome data for ibezapolstat, its lead antibiotic candidate, from its recently completed Phase 2b clinical trial in patients with Clostridoides difficile infection or CDI.
RTTNews
|
Pred 494 dňami
Acurx Pharma Discontinues Phase 2b Trial For Ibezapolstat To Treat C. Difficile Infection
Biopharmaceutical company Acurx Pharmaceuticals, Inc. (ACXP) announced Monday that the Company has discontinued the Phase 2b clinical trial of its lead antibiotic candidate, ibezapolstat, for the treatment of patients with Clostridioides difficile infection (CDI) due to success.
RTTNews
|
Pred 601 dňami
Acurx Pharma's Phase 2b Study Of Ibezapolstat In C. Difficile Infection On Track
Acurx Pharmaceuticals, Inc. (ACXP), while reporting financial results for the second quarter, on Monday, provided an update on its pipeline progress.
RTTNews
|
Pred 650 dňami
